The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...

The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.

Savannah Mendoza used to spend most of her paychecks on food delivery apps and at fast food drive-thrus, trying to satisfy a ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. If you’re starting a weight loss journey, you might have ...

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

The FDA on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will put ...

The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli ...

Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

Eli Lilly continues to break new ground. Its famous weight loss medicine, Zepbound (tirzepatide), just became the first to ...

GLP-1 receptor agonist weight loss drugs can negatively interact with eating disorder psychopathology and treatment in ...